Antipsychotics for elderly patients

Antipsychotics in older adults carry stroke and mortality warnings and require careful selection. Quetiapine and risperidone are most commonly used at low doses. Cobenfy and aripiprazole are lower-risk options. Boxed warning framing and non-drug alternatives first.

Medically reviewed by Shariq Refai, MD, MBA Last reviewed: July 2026

Quick answer

Antipsychotics in older adults carry a FDA black box warning for increased mortality in dementia-related psychosis and a stroke warning. Non-drug interventions come first (environmental modification, caregiver strategies, addressing underlying medical issues, pain control). When medication is needed, low-dose quetiapine (25 to 100 mg), risperidone (0.25 to 1 mg), or aripiprazole (2 to 10 mg) are typical choices. Rexulti (brexpiprazole) was FDA-approved specifically for Alzheimer's agitation in 2023. Cobenfy (xanomeline-trospium) has no D2 blockade so it may be safer for parkinsonism-vulnerable patients, though real-world dementia data is still emerging. Avoid haloperidol IV at high doses in delirium (QT), avoid olanzapine (metabolic burden and anticholinergic), avoid clozapine outside specific indications.

The black box warning

The FDA added a boxed warning to all second-generation antipsychotics in 2005, and to first-generation antipsychotics in 2008, for increased mortality (roughly 1.6 to 1.7 fold) in elderly patients with dementia-related psychosis. Absolute risk: about 4.5 percent mortality on drug vs 2.6 percent on placebo over 10 weeks. Cause of death typically cardiovascular or infectious.

The warning applies to all-cause mortality in the dementia population, not just antipsychotic-specific mortality. It reflects that antipsychotics are a real treatment with real risks in this population, not that they should never be used.

Clinical framework: try non-drug interventions first, use lowest effective dose, discuss risks with family, document informed consent.

Non-drug interventions first

Assess for underlying medical causes (infection, pain, medication side effects, sleep disturbance, environmental changes)
Environmental modification (calm environment, familiar people, routine)
Caregiver education (behavioral strategies, communication skills)
Nonpharmacologic activities (music therapy, reminiscence)
Address delirium precipitants

When medication is needed

For dementia-related agitation and psychosis:

Rexulti (brexpiprazole): FDA-approved June 2023 for Alzheimer's agitation. First drug with specific FDA approval for this indication. Dose 0.5 to 3 mg per day. Modest efficacy, boxed warning still applies but favorable side effect profile.
Aripiprazole (Abilify): 2 to 10 mg per day. Less metabolic risk than olanzapine. Some data supports use.
Quetiapine (Seroquel): 25 to 100 mg per day. Commonly used off-label. Sedation may be helpful. Some evidence for benefit, though effect sizes small.
Risperidone (Risperdal): 0.25 to 1 mg per day. Used for aggression. Higher EPS risk than atypicals above.

For delirium:

Low-dose haloperidol (0.25 to 1 mg PO or IM) for severe agitation with monitoring
Quetiapine or olanzapine at low doses in some centers
Avoid high-dose IV haloperidol due to QT

For psychosis in Parkinson's disease (drug-induced or from disease):

Pimavanserin (Nuplazid): 5-HT2A inverse agonist, approved specifically for Parkinson's psychosis. No D2 blockade. Modest efficacy.
Clozapine at low dose (12.5 to 50 mg): only antipsychotic well tolerated in Parkinson's disease. Requires ANC monitoring.
Quetiapine at low dose: often used off-label in Parkinson's.

Cobenfy (xanomeline-trospium) may become important for dementia-related psychosis because it does not block D2. Real-world data in dementia is limited. See our Cobenfy state of practice.

Drugs to usually avoid

Olanzapine (Zyprexa): Metabolic burden, anticholinergic activity, sedation. Not typical first choice in older adults.
Chlorpromazine, thioridazine: Anticholinergic, orthostasis, QT.
Haloperidol at high dose: QT prolongation, EPS.
Ziprasidone (Geodon): QT concerns; food requirement complicates dosing.
Iloperidone (Fanapt): Orthostasis.

Key considerations

Stroke risk: 1.7 fold increase with atypical antipsychotics in dementia patients.

Falls: All antipsychotics increase fall risk in elderly. Sedating drugs more so.

Orthostatic hypotension: More common in elderly. Alpha-1 antagonism worsens.

Anticholinergic burden: Adds to cognitive impairment. See anticholinergic burden page.

QT prolongation: See QTc page. More concerning in older adults on multiple QT drugs.

Metabolic effects: Less relevant in short-term use for behavioral symptoms; more relevant for chronic use.

Duration: Reassess need every 3 months. Deprescribing trials in dementia agitation show many patients tolerate discontinuation.

Dosing principles

Start at 25 to 50 percent of the usual adult starting dose
Titrate very slowly
Reassess frequently
Document indication clearly
Use time-limited trials when possible

Common questions

Is it ever appropriate to use antipsychotics in dementia patients? Yes, for severe agitation or psychosis that is dangerous, distressing, or unresponsive to non-drug measures. The boxed warning is a real risk consideration but not an absolute prohibition. Family and clinician informed decision-making.

Which antipsychotic is safest in Parkinson's disease? Clozapine at low dose has the best evidence but requires ANC monitoring. Pimavanserin has an FDA indication for Parkinson's psychosis. Quetiapine at low dose is commonly used off-label. Avoid drugs with substantial D2 blockade (risperidone, haloperidol, olanzapine) which worsen motor symptoms.

Should the antipsychotic ever be stopped? Yes, reassess every 3 months. Many dementia patients tolerate discontinuation. Trials of dose reduction or discontinuation are appropriate.

What about pimavanserin for Alzheimer's psychosis? Off-label for Alzheimer's psychosis. Some trials have not shown consistent benefit for this specific indication. FDA-approved specifically for Parkinson's psychosis.

Are non-antipsychotic alternatives helpful? Yes: trazodone, mirtazapine, citalopram (though QT concerns), SSRIs for depression-related agitation. Non-drug interventions are always first-line.

Sources

FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. April 2005.
Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546.
Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia. Am J Geriatr Psychiatry. 2020;28(4):383-400.
FDA prescribing information for Rexulti updated 2023 for Alzheimer's agitation indication.
American Geriatrics Society 2023 Updated AGS Beers Criteria.

THE KNOWLEDGE PATH

Walk this topic outward.

The Knowledge Path is a curated walk. Every step is one decision away from the next.

Your next step in The Shrink Network

You are here: PsychiatryRx, the medication education layer of The Shrink Network.

Every site in the network does one job. No matter where you start, we help you find the next step that makes sense.

Medication management at shrinkMD

shrinkMD is the network's independent telepsychiatry practice, founded by our medical editor. It's one option among many. PsychiatryRx runs no ads, sells nothing, and earns no referral fees.

Want to understand more first?

When the current regimen is not working

A page like this can explain why one drug is different from another. Whether a specific change makes sense for your history is a conversation with your prescriber.

shrinkMD (telepsychiatry)

Independent multistate telepsychiatry practice founded by Shariq Refai, MD, MBA, the medical editor of this site. Evaluations, medication management, and ongoing care for adults.

Visit shrinkMD →

Your existing prescriber

If you already have a psychiatrist, primary care clinician, or nurse practitioner managing your medications, they are the right first stop for questions raised by this page.

Other telepsychiatry options

Directory-style guides on finding a prescriber, including state-by-state resources and non-telehealth options.

AnxietyResource guide → DepressionResource guide →

Reference guides like this one belong beside a conversation with a prescriber. If this raises questions about your specific regimen, that conversation is the next step.

Disclosure (FTC 255): shrinkMD is founded by Shariq Refai, MD, MBA, who is also the medical editor of PsychiatryRx.org. He has a financial interest in shrinkMD. PsychiatryRx takes no fees, commissions, or referral revenue from shrinkMD or any other prescriber. shrinkMD is presented as one option among many, not a personalized recommendation. Every reader is free to choose any prescriber. This page does not create a doctor-patient relationship.

Managing a medication needs a prescriber

Any psychiatric medication has to be started and adjusted by a clinician who can follow you over time. If you don't have a prescriber, our guides section explains the options, including in-person care and telepsychiatry, and how to choose between them.